title: Different degrees of GH deficiency evidenced by GHRH+arginine test and IGF-I levels in adults with pituritary disease.
abstract: To verify if the entity of the peak GH responses to the GHRH+arginine (ARG) test is able to show different degree forms of GH deficiency (GHD), we linked these responses with the number of other anterior pituitary deficits. These anterior pituitary deficits were also related with IGF-I levels. To this purpose, we studied a large cohort of lean patients with pituitary disease of different etiologies [86 males and 68 females; age: mean +/- SEM 41.5 +/- 1.2 yr, body mass index (BMI) <25 kg/m2]. The patients were subdivided into 4 groups according to the increasing number of hormone deficiencies: isolated GHD (HYPO1, no.=28) or GHD plus one, two or three additional hormones (gonadotrophin, ACTH, and TSH) deficiencies (HYPO2, no.=20; HYPO3, no.=15; HYPO4, no.=91). Peak GH responses to the GHRH+ARG test and IGF-I levels showed a clear difference among the groups (p < 0.01 and p < 0.001, respectively). A significant difference was found between HYPO1 and HYPO4 for IGF-I levels (p < 0.05), and between HYPO1 and HYPO4 and between HYPO2 and HYPO4 for the GHRH+ARG test (p < 0.005). Considering only the patients who underwent both GHRH+ARG test and insulin tolerance test (ITT) (no.=70), the pattern of the peak GH responses to the GHRH+ARG test was the same of the whole group of patients, while no statistical difference was found with ITT. Our data show that the peak GH responses to the GHRH+ARG test and the IGF-I levels are linked to the severity of hypopituitarism, expressed by the number of increasing anterior pituitary deficits. This association is lost if the evaluation of the GH status is performed by the ITT. In all, the GHRH+ARG test and measurement of IGF-I are able to evidence different degrees of GHD in adult patients with pituitary disease.
authors.affiliation: Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, University of Turin, Italy. gianluca.aimaretti@unito.it
authors.forename: G
authors.initials: G
authors.lastname: Aimaretti
authors.forename: G
authors.initials: G
authors.lastname: Corneli
authors.forename: C
authors.initials: C
authors.lastname: Di Somma
authors.forename: R
authors.initials: R
authors.lastname: Baldelli
authors.forename: V
authors.initials: V
authors.lastname: Gasco
authors.forename: S
authors.initials: S
authors.lastname: Rovere
authors.forename: G
authors.initials: G
authors.lastname: Migliaretti
authors.forename: A
authors.initials: A
authors.lastname: Colao
authors.forename: G
authors.initials: G
authors.lastname: Tamburrano
authors.forename: G
authors.initials: G
authors.lastname: Lombardi
authors.forename: E
authors.initials: E
authors.lastname: Ghigo
authors.forename: F
authors.initials: F
authors.lastname: Camanni
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001120:Arginine; D002675:Child, Preschool; D005260:Female; D013007:Growth Hormone-Releasing Hormone; D019382:Human Growth Hormone / Q000097:blood / Q000172:deficiency*; D006801:Humans; D007018:Hypopituitarism / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures; D010911:Pituitary Neoplasms / Q000150:complications / Q000601:surgery
chemical_list: D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I; D013007:Growth Hormone-Releasing Hormone; D001120:Arginine